Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of December 2019
Filing Date: December 12, 2019
This filing serves as a cover document for the submission of Exhibit 99.1 (Appendix 3B). The registrant is an Irish-domiciled company with principal executive offices in Dublin, Ireland, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing referencing an exhibit rather than a financial results report.
Material Changes
The filing text does not disclose specific material changes in financial performance or operations versus the prior comparable period. It references the integration of Fermacell into the business as a risk factor but provides no quantitative update on this integration within this specific text.
Guidance, Outlook, and Risks
Forward-Looking Statements: The document contains an extensive disclaimer regarding forward-looking statements. These include projections on future performance, capital expenditure projects, credit facility renewals, dividend payments, and share buy-backs.
Key Risks and Contingencies:
- Asbestos Liability: Significant exposure related to prior manufacture of asbestos-containing products, including required contributions to the Asbestos Injuries Compensation Fund (AICF) and potential shortfalls.
- Legal and Regulatory: Exposure to product liability, environmental, and consumer class action proceedings.
- Market Conditions: Dependence on residential and commercial construction markets, housing values, and consumer confidence in the US and Asia Pacific regions.
- Operational Risks: Costs associated with plant suspensions or closures, raw material supply and costs, and currency exchange rate fluctuations.
- Financial Risks: Uncertainty regarding the discontinuance of LIBOR and the ability to renew credit facilities on favorable terms.
Investor Verification Checklist
- Review Exhibit 99.1 (Appendix 3B), which is referenced but not included in the provided text, for specific financial data or operational updates.
- Verify the current status and funding adequacy of the Asbestos Injuries Compensation Fund (AICF) and any recent changes to contribution estimates.
- Monitor currency exchange rates (USD/AUD/EUR) given the company's international operations and the specific risk noted regarding asbestos liability valuation.
- Assess the progress of the Fermacell integration and its impact on operational costs and synergies.
- Check for updates on credit facility terms and covenants, particularly regarding the transition from LIBOR.